LUMIBIRD : Hesitation should subside in favor of volatility
| Entry price | Target | Stop-loss | Potential |
|---|
|
€21.15 |
€24.2 |
€19.74 |
+14.42% |
|---|
From a horizontal accumulation phase, the timing seems good to buy shares in LUMIBIRD and to get ahead of a break-out on the upside of the congestion area.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
● Consensus analysts have strongly revised their opinion of the company over the past 12 months.
● The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
● The group usually releases upbeat results with huge surprise rates.
● With an expected P/E ratio at 31.95 and 24.86 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
● The valuation of the company is particularly high given the cash flows generated by its activity.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
LUMIBIRD 
